Clinical Trial

A Phase 1 Study to Investigate FP008 in Subjects With Advanced Solid Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The goal of the phase 1 study is to evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics activity of FP008 in subjects with advanced solid tumors.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-05-18; most recent amendment 2025-09-28.
Status change: Not Yet Recruiting → Recruiting 2025-07-09
Trial Details
NCT Number NCT06990698
Lead Sponsor Zhuhai Fapon Biopharma Co., Ltd.
Conditions Advanced Solid Tumors
Enrollment 108 participants
Start Date 2025-06-12
Primary Completion 2028-05 (estimated)
Study Completion 2028-09 (estimated)
Updated on ClinicalTrials.gov 2026-08-12